Ethical considerations for involving adolescents in biomedical HIV prevention research.
Adolescent girls
Biomedical HIV prevention research
Ethics
Stakeholder engagement
Uganda
Journal
BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680
Informations de publication
Date de publication:
23 09 2021
23 09 2021
Historique:
received:
30
03
2021
accepted:
07
09
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Involvement of adolescent girls in biomedical HIV research is essential to better understand efficacy and safety of new prevention interventions in this key population at high risk of HIV infection. However, there are many ethical issues to consider prior to engaging them in pivotal biomedical research. In Uganda, 16-17-year-old adolescents can access sexual and reproductive health services including for HIV or other sexually transmitted infections, contraception, and antenatal care without parental consent. In contrast, participation in HIV prevention research involving investigational new drugs requires adolescents to have parental or guardian consent. Thus, privacy and confidentiality concerns may deter adolescent participation. We describe community perspectives on ethical considerations for involving adolescent girls in the MTN 034 study in Uganda. From August 2017 to March 2018, we held five stakeholder engagement meetings in preparation for the MTN 034 study in Kampala, Uganda (NCT03593655): two with 140 community representatives, two with 125 adolescents, and one with 50 adolescents and parents. Discussions were moderated by the study team. Proceedings were documented by notetakers. Summary notes described community perspectives of adolescent participation in HIV research including convergent, divergent or minority views, challenges, and proposed solutions. Most community members perceived parental or guardian consent as a principal barrier to study participation due to concerns about adolescent disclosure of pre-marital sex, which is a cultural taboo. Of 125 adolescent participants, 119 (95%) feared inadvertent disclosure of sexual activity to their parents. Community stakeholders identified the following critical considerations for ethical involvement of adolescents in HIV biomedical research: (1) involving key stakeholders in recruitment, (2) ensuring confidentiality of sensitive information about adolescent sexual activity, (3) informing adolescents about information to be disclosed to parents or guardians, (4) offering youth friendly services by appropriately trained staff, and (5) partnering with community youth organizations to maximize recruitment and retention. Stakeholder engagement with diverse community representatives prior to conducting adolescent HIV prevention research is critical to collectively shaping the research agenda, successfully recruiting and retaining adolescents in HIV clinical trials and identifying practical strategies to ensure high ethical standards during trial implementation.
Sections du résumé
BACKGROUND
Involvement of adolescent girls in biomedical HIV research is essential to better understand efficacy and safety of new prevention interventions in this key population at high risk of HIV infection. However, there are many ethical issues to consider prior to engaging them in pivotal biomedical research. In Uganda, 16-17-year-old adolescents can access sexual and reproductive health services including for HIV or other sexually transmitted infections, contraception, and antenatal care without parental consent. In contrast, participation in HIV prevention research involving investigational new drugs requires adolescents to have parental or guardian consent. Thus, privacy and confidentiality concerns may deter adolescent participation. We describe community perspectives on ethical considerations for involving adolescent girls in the MTN 034 study in Uganda.
METHODS
From August 2017 to March 2018, we held five stakeholder engagement meetings in preparation for the MTN 034 study in Kampala, Uganda (NCT03593655): two with 140 community representatives, two with 125 adolescents, and one with 50 adolescents and parents. Discussions were moderated by the study team. Proceedings were documented by notetakers. Summary notes described community perspectives of adolescent participation in HIV research including convergent, divergent or minority views, challenges, and proposed solutions.
RESULTS
Most community members perceived parental or guardian consent as a principal barrier to study participation due to concerns about adolescent disclosure of pre-marital sex, which is a cultural taboo. Of 125 adolescent participants, 119 (95%) feared inadvertent disclosure of sexual activity to their parents. Community stakeholders identified the following critical considerations for ethical involvement of adolescents in HIV biomedical research: (1) involving key stakeholders in recruitment, (2) ensuring confidentiality of sensitive information about adolescent sexual activity, (3) informing adolescents about information to be disclosed to parents or guardians, (4) offering youth friendly services by appropriately trained staff, and (5) partnering with community youth organizations to maximize recruitment and retention.
CONCLUSIONS
Stakeholder engagement with diverse community representatives prior to conducting adolescent HIV prevention research is critical to collectively shaping the research agenda, successfully recruiting and retaining adolescents in HIV clinical trials and identifying practical strategies to ensure high ethical standards during trial implementation.
Identifiants
pubmed: 34556099
doi: 10.1186/s12910-021-00695-3
pii: 10.1186/s12910-021-00695-3
pmc: PMC8461968
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
127Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068633
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068615
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106707
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069530
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW010695
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Arch Dis Child. 2014 Oct;99(10):887-91
pubmed: 24914095
Clin Pract Pediatr Psychol. 2018 Sep;6(3):299-307
pubmed: 30393589
Paediatr Int Child Health. 2016 Feb;36(1):58-63
pubmed: 25362964
J Adolesc Health. 2019 Apr;64(4):427-429
pubmed: 30904091
BMC Pediatr. 2017 May 8;17(1):120
pubmed: 28482854
J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1:S12-7
pubmed: 20571418
J Int AIDS Soc. 2014 Sep 08;17(3 Suppl 2):19149
pubmed: 25224611
BMC Med Ethics. 2007 May 13;8:5
pubmed: 17498316
J Adolesc Health. 2016 May;58(5):576-8
pubmed: 26976148
PLoS Med. 2006 Jul;3(7):e180
pubmed: 16608384
J Adolesc Health. 2015 Jan;56(1 Suppl):S7-14
pubmed: 25528980
Dev World Bioeth. 2015 Dec;15(3):191-8
pubmed: 24910162
Lancet. 2010 Jul 3;376(9734):41-8
pubmed: 20557928
AIDS. 2017 Jun 19;31(10):1461-1470
pubmed: 28426534
J Adolesc Health. 2008 Jan;42(1):3-10
pubmed: 18155024